Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report)'s stock price traded up 5.7% during mid-day trading on Monday . The company traded as high as $17.14 and last traded at $17.14. 27,223 shares changed hands during trading, a decline of 93% from the average session volume of 363,530 shares. The stock had previously closed at $16.21.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on UPB shares. William Blair started coverage on Upstream Bio in a report on Tuesday, November 5th. They issued an "outperform" rating for the company. Piper Sandler initiated coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They issued an "overweight" rating and a $75.00 target price for the company. JPMorgan Chase & Co. initiated coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They set an "overweight" rating and a $38.00 price target on the stock. Finally, TD Cowen began coverage on Upstream Bio in a research report on Tuesday, November 5th. They set a "buy" rating on the stock.
Get Our Latest Stock Report on UPB
Upstream Bio Trading Up 10.6 %
The firm has a 50 day moving average price of $22.69.
Upstream Bio (NASDAQ:UPB - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($6.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($6.38). The firm had revenue of $0.61 million for the quarter, compared to analysts' expectations of $0.83 million. On average, equities analysts expect that Upstream Bio, Inc. will post -4.3 EPS for the current year.
Insider Transactions at Upstream Bio
In other Upstream Bio news, major shareholder Ai Upstream Llc acquired 1,175,000 shares of the company's stock in a transaction that occurred on Tuesday, October 15th. The shares were bought at an average cost of $17.00 per share, with a total value of $19,975,000.00. Following the completion of the transaction, the insider now directly owns 1,175,000 shares of the company's stock, valued at approximately $19,975,000. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Erez Chimovits bought 825,000 shares of the firm's stock in a transaction on Tuesday, October 15th. The stock was acquired at an average cost of $17.00 per share, with a total value of $14,025,000.00. Following the transaction, the director now owns 4,554,873 shares in the company, valued at $77,432,841. The trade was a 22.12 % increase in their position. The disclosure for this purchase can be found here.
About Upstream Bio
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
See Also
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
